Genomic Health's management team has extensive experience in a variety of cutting-edge technical fields including the molecular diagnostics, information technology, biotechnology, pharmaceutical and genomic industries. Team members have demonstrated continued success in starting businesses, researching and developing novel drugs, launching products, building successful organizations and delivering value to shareholders.
- Kimberly Popovits, Chairman of the Board, Chief Executive Officer & President
- G. Bradley Cole, Chief Operating Officer and Chief Financial Officer
- Steven Shak, M.D., Co-Founder, Chief Scientific Officer
- Frederic Pla, Ph.D., Chief Business & Product Development Officer
- Jim Vaughn, R.Ph., Chief Commercial Officer
- Phil Febbo, M.D., Chief Medical Officer
- Laura Leber, Chief Communications Officer
- Kim McEachron, Chief People Officer
- Jason Radford, Chief Legal Officer & Secretary
- Paul Aldridge, Ph.D., Senior Vice President, Software Technology and
Chief Information Officer
- Joffre Baker, Ph.D., Co-Founder, Senior Biology Fellow
- Ellen Beasley, Ph.D., Senior Vice President, Products and Services R&D
- Jon Cassel, Ph.D, Senior Vice President, Operations
Kimberly Popovits, Chairman of the Board, Chief Executive Officer & President
"Like many of my colleagues, it is my personal experience with cancer that drives my passion to change the way we diagnose and treat this complex disease that touches so many lives. As we gain greater understanding of the biology of cancer, we have an opportunity and a responsibility to develop tools that arm both physicians and patients with personalized genomic information to individualize the treatment of a patient´s disease. With the advent of biologics and new targeted therapeutics, the menu of treatment options for patients with cancer is growing. It is our mission to develop tests that employ the biology of an individual´s specific tumor to help physicians select appropriate treatments from this expanding menu. We are entering an era where we have the information and means to transform "one-size-fits-all" medicine to a world where treatment is truly personalized. We remain steadfast in our mission to provide cancer patients with access to information that can empower them to better manage their disease. Oncotype DX is the beginning. Our commitment is to set no limit on the end."
Committed to changing the paradigm of cancer care, Kim Popovits has led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that address the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. Kim has served as Genomic Health’s Chairman of the Board since 2012, and Chief Executive Officer and President since 2009. She was President and Chief Operating Officer since joining the company in 2002. Prior to joining Genomic Health, Kim served as Senior Vice President, Marketing and Sales at the biotechnology company, Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Before joining Genentech, Kim served as division manager for American Critical Care, a division of American Hospital Supply Corporation. Kim currently serves on the boards of the California Life Sciences Association (CLSA), the Personalized Medicine Coalition (PMC), the American Clinical Laboratory Association (ACLA), and ZS Pharma. Kim is also the President of The Coalition for 21st Century Medicine, and serves as an Advisor to the Healthcare Businesswomen’s Association (HBA). Kim’s contributions to science and the commercialization of the biotechnology industry have been acknowledged by multiple organizations including being named Most Admired CEO in 2014 as well as one of the Most Influential Women in the Bay Area from 2006-2012 by the San Francisco Business Times. She was also named Woman of the Year in 2008 by the Women Health Care Executives. Kim holds a Bachelor of Arts degree in Business from Michigan State University.
G. Bradley Cole, Chief Operating Officer and Chief Financial Officer
"Success is defined many times in life as doing something very well and sometimes only one thing. That can be true in business as well, and we have chosen treatment for patients with cancer as a singular focus by which to measure success. In doing so we have the opportunity to do the right thing very well for the benefit of medicine, patients, physicians, payers and the healthcare system overall. Having seen both family members and friends die from cancer in recent years, I can think of no better way to spend my day than helping others who will be faced with similar circumstances in the future.”
Brad Cole has been influential in steering Genomic Health Inc. through its initial public offering in 2005, delivering the company’s first full year of profit in 2010 and expanding the business oversees in an effort to reach cancer patients around the world. Brad has held the title of Chief Operating Officer at Genomic Health Inc. since 2009, prior to his current dual role as Chief Operating Officer and Chief Financial Officer. Brad was also the Chief Financial Officer and Executive Vice President of the company from 2004 until 2008. Before joining Genomic Health, Brad served in various positions at Guidant Corporation, a designer and developer of cardiovascular medical products. At Guidant, Brad served as Vice President, Finance and Business Development for the Endovascular Solutions Group from 2001 until 2004. Prior to that, he served as Vice President and General Manager of the Vascular Surgery Business Unit of Guidant. Brad was Vice President, Finance and Chief Financial Officer of Endovascular Technologies, Inc., a publicly traded medical device company acquired by Guidant Corporation in 1997. Previously, Brad was Vice President and Chief Financial Officer of Applied Biosystems, a publicly traded life sciences company. Brad holds a Bachelor of Science degree in Business from Biola University and an MBA from San Jose State University.
Steven Shak, M.D., Co-Founder, Chief Scientific Officer
"We urgently need new and more effective approaches to cancer diagnosis, treatment, and prevention.
In the 20th century, with few diagnostic tests to select the right treatment for individual cancers, physicians treated cancer with a “one size fits all” approach.
At Genomic Health, we have developed innovative, standardized, quantitative methods for profiling individual cancers. Cancer drugs can be (targeted) if we are able to discover and develop diagnostic tests to identify which patients are likely to benefit from them. We are using the same rigorous approach used in the clinical development and validation of the Oncotype DX Breast Cancer Assay to develop tests for other tumor types. We passionately believe that cancer molecular diagnostics will play an indispensable role in treatment planning for all cancer patients and will help turn cancer into a manageable, and ultimately preventable, disease. "
Dedicated to optimizing cancer treatment outcomes and bringing the patient voice into product development, Steve Shak, M.D. has served as the Co-Founder, Chief Scientific Officer since 2012 and was the Chief Medical Officer from 2000 - 2013. Under Steve's leadership Genomic Health used innovative molecular diagnostic methods and rigorous clinical studies to develop the Oncotype DX® breast cancer and colon cancer assays and has maintained an 80% product development success rate. Steve has been a leader in personalized medicine for more than two decades. Prior to co-founding Genomic Health in 2000, Steve served for 14 years in various roles in Discovery Research and Medical Affairs at Genentech, Inc., a biotechnology company dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Steve led the clinical team that gained approval for Herceptin®, a targeted biologic treatment for breast cancer. He also initiated the cancer clinical trials of the anti-angiogenesis agent, Avastin®. In addition, Steve discovered Pulmozyme®, a mucus-dissolving enzyme that is approved worldwide for the treatment of the genetic disease cystic fibrosis. Prior to joining Genentech, Steve was an Assistant Professor of Medicine and Pharmacology at New York University School of Medicine. Steve holds a Bachelor of Arts degree in Chemistry from Amherst College and an M.D. from New York University School of Medicine, and completed his post-doctoral training at University of California, San Francisco.
Frederic Pla, Ph.D., Chief Business & Product Development Officer
"Like many in this field, working in healthcare technology was a deliberate and very personal decision, and I’m deeply grateful to be part of Genomic Health’s mission. My passion and strength is in building high-growth businesses in healthcare technologies through innovative combinations of technologies and business models. Impacting the lives of cancer patients is immensely gratifying and comes with incredible responsibility, since progress and success is directly measured by the number of patient lives we can change. Genomic Health has shifted the paradigm in cancer disease management, benefiting hundreds of thousands of patients. The vision, boldness and tenacity that made Genomic Health what it is are in full force today, as we push forward on our journey to redefine cancer care by combining new diagnostic and information technologies, continuing to lead our industry. This is not just a passion for our incredible team, but a responsibility. I am proud to be a part of it."
Over the last 25 years, Frederic Pla has built and launched global businesses in medical diagnostics and devices, life sciences, and healthcare information technology, consistently delivering high growth and profitability through a blend of product innovation, strategic acquisitions, and successful turnarounds. Before joining Genomic Health in 2014 as Chief Business & Product Development Officer, Frederic was the Vice President, Corporate Business Development, for Life Technologies, a $4 billion, 11,000 employee, San Diego-based global life sciences business, until its acquisition by Thermo Fisher in 2014. Frederic led many of the company’s internal and external growth initiatives, adding nearly $2.5 billion in yearly revenue through 30 acquisitions across areas such as diagnostics, food safety and animal health, bioinformatics and life sciences tools. Frederic joined Life Technologies in 2005 as Vice President and General Manager of the Diagnostics Business, responsible for product development and manufacturing facilities in the US, UK, and China. Under Frederic’s leadership, this global business provided physicians with a complete set of tools to aid in solid organ and bone marrow transplant diagnostics, sold worldwide through a dedicated global sales force and distributor network. Prior to joining Life Technologies, Fred held global managerial positions of increasing responsibilities at GE Healthcare, including General Manager for the Cardiology IT and Enterprise IT businesses, where Frederic contributed to the formation and growth of GE’s $2.4 billion Healthcare IT business; and Digital X-Ray Marketing, where he led the introduction of GE’s revolutionary digital X-Ray detector technology. Frederic started his career in R&D, first at the NASA Glenn Research Center in Cleveland, OH, and then at GE’s Global Research Center in Schenectady, NY. He is fluent in French, holds 23 U.S. patents, a Ph.D. in Acoustics from the Pennsylvania State University, a Master’s Degree from The University of Southampton, UK, and an Engineering Degree from the University of Technology of Compiegne, France.
Jim Vaughn, R.Ph., Chief Commercial Officer
“It is a privilege to help bring the advances of personalized medicine to our patients and physicians worldwide. At Genomic Health, our scientists have collaborated with many of the most talented research groups in the world and I take great pride in being able to provide our patients, physicians, and insurance providers with the data and confidence they require to make critical, rational, and individualized treatment decisions.”
Committed to expanding patient access to Genomic Health’s tests, Jim currently serves as Chief Commercial Officer, and oversees US and International sales, marketing, reimbursement and customer support efforts. Most recently, Jim led the US Marketing teams and portfolio planning for both near and long-term strategy. From 2009 through 2012, Jim drove the expansion of Genomic Health’s international business efforts in Geneva, Switzerland. In Geneva, Jim and team focused on collaborating with early adopting physicians in Canada, Ireland, Spain, Germany, and the UK, to support broader Oncotype DX reimbursement and patient access. These pioneering efforts, coupled with the experience that physicians across Europe had with the test, led to the inclusion of the Oncotype DX Breast Cancer Assay in the prestigious St. Gallen guidelines in 2011. Prior to leading the marketing teams at Genomic Health, Jim worked in the managed care setting and led Genomic Health’s Western U.S. sales efforts from 2005 through 2008. Before joining Genomic Health, Jim was Vice President of Cerus Corporation, a biomedical products company, where he directed marketing and medical affairs. Prior to this appointment, Mr. Vaughn held a number of positions in sales, sales management, and marketing, including the role as Senior Director of Global Oncology Franchise with Celebrex. Jim holds a Bachelor of Science degree in Pharmacy from Creighton University and an MBA from Northwestern University, Kellogg School of Business.
Phil Febbo, M.D., Chief Medical Officer
"Having dedicated my career to improving the clinical care of men and women diagnosed with cancer through molecular insight enabled by genomics, I am thrilled to contribute to Genomic Health's mission to limit overtreatment while at the same time expanding the number of individuals who can potentially benefit. With nearly 400,000 patients having benefitted from our tests and our proven "team science" approach, I am confident that this is just the beginning."
After 20 years as a physician scientist at leading Institutes throughout the country, Phil Febbo, joined Genomic Health as Chief Medical Officer in 2013. Immediately prior to Genomic Health, Phil served as Professor of Medicine and Urology at the University of California, San Francisco where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer and his clinical practice focused on genitourinary oncology. While at UCSF, Phil was the Co-Leader of the Prostate Cancer Program at the UCSF Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. Phil holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at the University of California, San Francisco and completed Internal Medicine Residency at the Brigham and Women' s Hospital in Boston, Massachusetts. After his fellowship in Medical Oncology at the Dana Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at the Dana Farber Cancer Institute, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at the Dana Farber Cancer Institute as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 2004, Phil moved to Duke University Medical Center’s Institute of Genome Sciences and Policy. In 2010, he returned to UCSF. Phil’s laboratory was funded by the NIH, DOD, Damon Runyon Cancer Research Foundation, and the Prostate Cancer Foundation. He has been a member of the American Society for Clinical Investigation since 2009.
Laura Leber, Chief Communications Officer
"It’s thrilling to be part of a company from its early days and to witness a group of smart, passionate people bring a vision to reality, but it is a real privilege to be responsible for telling the world about it. The story of Oncotype DX and the power of personalized medicine is one that has captured a lot of attention. Our success in leading the clinical application of personalized medicine is a result of the commitment of the employees of Genomic Health who insisted on scientific and clinical rigor and on world-class customer support for physicians and patients. And it would not have happened if not for the brave heroes -- the breast, colon and prostate cancer patients -- whose stories shape, inform and inspire our work on a daily basis. And best of all, Genomic Health’s story has just begun!"
Laura Leber has led the company’s efforts to tell Genomic Health’s story since 2002. In her current role as Chief Communications Officer, Laura is responsible for global communications to media, investor, advocate, government, patient and employee audiences. Prior to joining Genomic Health, Laura worked in various communications roles at Genentech, Inc., a leading biotechnology company, from 1992 until 2001, most recently as Vice President, Corporate Communications, where she was responsible for the company´s worldwide communications function. Before joining Genentech, Laura held various positions in Corporate Communications and Public Relations for Searle, a pharmaceutical company in Chicago, and at Fleishman-Hillard, Inc. in St. Louis and Hill and Knowlton, Inc. in New York City, both global public relations agencies. Laura holds a Bachelor of Journalism degree from the University of Missouri, Columbia.
Kim McEachron, Chief People Officer
“It is rare to be part of a senior management team with such a passion to empower patients on their health care journey and an equivalent desire to support a healthy, vibrant culture. I feel privileged to work with so many extraordinary people, in an organization that is designing a new era in health care through our innovations in the field of personalized medicine. As the company continues to grow and diversify, I am excited to support our global expansion, through the attraction and development of top talent.”
Kim McEachron brings over 20 years of human resources experience, both from entrepreneurial and large company environments to the Genomic Health team. Throughout her career, Kim has focused on designing experiences and cultures to inspire individuals, teams, and organizations to reach their full potential. Since joining the company in 2012, as Chief People Officer, Kim has been responsible for the alignment of strategic, operational and organizational human resource processes to build capabilities for growth. Prior to joining the company, Kim held several leadership roles within Medtronic, Inc., a global leader in medical technologies that improves the way chronic diseases are treated. From 2010 – 2012, Kim was the Vice President of Human Resources, Engagement and Inclusion for the Medtronic Cardiac and Vascular division. In prior roles at Medtronic, Kim was responsible for the implementation of total rewards programs; diversity and inclusion strategies; talent management systems; leadership development and executive coaching. Earlier in her career with Medtronic, Kim was Vice President of Human Resources for the CardioVascular and Neuromodulation divisions where her responsibilities included leading talent acquisition and management, organization development and learning, employee relations, and diversity. From this role, she contributed to the diversification and growth of the CardioVascular and Neuromodulation businesses by successfully integrating acquisitions and building capabilities. Kim holds a Master’s degree in Industrial Relations from University of Minnesota-Twin Cities and a Bachelor’s degree in Sociology and Anthropology from Carleton College. Kim is a former Chair of the Board and a current Board Member of the Sonoma County Volunteer Center. She holds memberships in Human Resource People and Strategy (HPRS), The HR Strategy Forum, and the Association for Managers of Innovation (AMI). In 2008 and 2010, Ms. McEachron was recognized for her corporate leadership in global diversity and inclusion at Medtronic, and in 2003, she received the Women in Business Award from the North Bay Business Journal.
Jason Radford, Chief Legal Officer & Secretary
“It is said that we are experiencing a new ‘Renaissance of Biology’ enabled by technological innovation fueling vigorous research and resulting in ground-breaking discoveries in the diagnosis, treatment, and monitoring of disease. Genomic Health has had – and will continue to have – a crucial role in this ‘Renaissance’ by being a pioneer and world leader in developing best-in-class genomic-based diagnostic tests that deliver critical information to physicians to better inform optimal treatment of a patient’s cancer care. I am privileged to be part of a company that has made it a mission to improve the lives of cancer patients while simultaneously lowering healthcare costs and improving the overall standard of care. As Genomic Health continues to be industry-leading in its development and commercialization of high-quality, clinically-actionable diagnostics, we will remain steadfast in our resolve to support the patient and medical community throughout the cancer patients’ journey.”
Committed to supporting Genomic Health deploy innovative diagnostics in support of ever-improved cancer care, Jason Radford serves as Chief Legal Officer and Secretary, and is head of the Legal Department. Prior to joining Genomic Health, Jason served as Executive Vice President and General Counsel at Accumen Inc., a provider of consulting services to health systems designed to improve laboratory operations and patient blood management. Prior to Accumen, Jason served as Division Lead Counsel for the Genetic & Medical Sciences business at Life Technologies Corporation, a global biotechnology and life sciences company now part of Thermo Fisher Scientific. Before joining Life Technologies, Jason was an attorney in the Corporate & Securities Group of DLA Piper LLP, an international law firm, where he served as outside counsel to public and private companies in a variety of commercial transactions. Jason earned his B.A. in Political Science at the University of California, Los Angeles; a J.D. from Boston College Law School; and an M.B.A. from the Wallace E. Carroll Graduate School of Management at Boston College.
Paul Aldridge, Ph.D., Senior Vice President, Software Technology and
Chief Information Officer
"Genomic Health is at the forefront of the revolution in healthcare and personalized medicine. We focus on delivering information, unique and critical to every patient, into the hands of healthcare professionals and patients that will drive treatment decisions and improve individual outcomes. The work of delivering timely, complete and accurate information to physicians and patients is the core mission of a team of dedicated Information Technology professionals. Everyday, we look for ways to improve the standard of care for cancer patients worldwide."
Leading the innovation behind the Information Technology group at Genomic Health, Paul Aldridge has served as the Senior Vice President, Software Technology and Chief Information Officer since 2009. Prior to joining Genomic Health, from 2003 to 2009, Paul served as Vice President, Global Information Technology at BIOGEN IDEC, Inc., a developer, manufacturer and marketer of biological products for the treatment of serious diseases with a focus on neurological disorders. Before that, Paul held several positions in Developmental Research and Information Technology at Pfizer Global R&D from 1991 to 2003. Paul is the author of three patents and over 40 scientific publications and presentations. He holds a Ph.D. and an M.S. in Analytical Chemistry from the University of Washington; and, a Bachelor of Science degree in Chemistry from California State University, Sacramento, and has served in the United States Coast Guard.
Joffre Baker, Ph.D., Co-Founder, Senior Biology Fellow
"Genomic Health was founded to take advantage of developments in three areas:
1) decades of worldwide accumulation of scientific knowledge about cancer pathology at the cellular, molecular and genomic level
2) the continuous development of increasingly sensitive and precise laboratory technologies for quantifying genomic information
3) the development of scientific computing technology that permits the storage and analysis of vast amounts of genomic information
It is an exciting fact that progress in each of these three areas continues at a rapid pace. As a result, it is clear that the era of personalized medicine for cancer patients has not only arrived, but has a very bright future."
Since co-founding the company in 2000, Joff Baker, Ph.D. has served as Co-Founder, Senior Biology Fellow and has overseen the research & development teams behind the breast, colon and prostate cancer programs at Genomic Health. Joff and his team are currently deploying Next Generation Sequencing technology and its application across all research initiatives in an effort to connect either gene mutations or expression profiles to clinical outcomes and provide additional personalized information to physicians and patients beyond that already available through the use of Oncotype DX®. Prior to cofounding Genomic Health in 2000, Joff served as Vice President for Research Discovery at Genentech, Inc., a biotechnology company, dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. From 1993 to 2000, Joff oversaw Research Discovery at Genentech, which included the Departments of Cardiovascular Research, Oncology, Immunology, Endocrinology and Pathology. From 1991 to 1993, he served as Genentech’s Director of Cardiovascular Research. Prior to joining Genentech, Joffre was a faculty member in the Department of Biochemistry at the University of Kansas. He holds a Bachelor of Science degree in Biology and Chemistry from the University of California, San Diego and a Ph.D. in Biochemistry from the University of Hawaii. Joff is the recipient of a NIH (National Institutes of Health) Research Career Development Award (1983 – 1988), and is the author of over 65 publications.
Ellen Beasley, Ph.D., Senior Vice President, Products and Services R&D
"I’ve had the great fortune of spending my career helping to define and then apply the human genome to improve health. Genomic Health is unique in its singular focus on improving the lives of cancer patients by applying genomic insights to critical decisions in a patient’s journey. It’s a privilege to lead our new product research and development efforts on liquid biopsy, we are developing exciting new technologies for future tests while maintaining our relentless focus on patient impact with today’s Oncotype DX tests. It’s an honor to be part of such a smart, dedicated and collaborative team."
Ellen Beasley has over 20 years of product development and program management experience in biotechnology and genomics sciences. She brings a record of successful integration and application of bioinformatics, genetics and genomics platforms to advance and accelerate life sciences instrument, diagnostics and therapeutics product discovery and development. Ellen started her career in human genomics at the Stanford Human Genome Center and lead the team developing physical maps of the human genome. She then moved to Celera Genomics and participated in the genome sequencing and gene discovery efforts for the human genome. After the completion of the human genome, Ellen managed various discovery efforts to apply the human genome, including drug target discovery efforts, investigation of the genetic basis of autoimmune disease and companion diagnostic partnership development. Ellen then moved to Perlegen Sciences where she was SVP of R&D Operations, managing companion diagnostic programs and building the CLIA lab for commercialization of a breast cancer risk assay. In 2009, Ellen joined Life Technologies and was VP of Biological Information Systems, leading a team to develop methods and software tools to exploit the data from next generation sequencers. Since joining Genomic Health in 2013, Ellen has focused on the application of next generation technologies, including sequencing and liquid-based biopsy, to discover and develop Genomic Health’s next generation of products to serve patients living with cancer. Ellen received a B.S. in Biology from Trinity College (Hartford, CT) and a Ph.D. in Molecular Genetics & Cell Biology from The University of Chicago, she completed post-doctoral training at the Biozentrum of the University of Basel in Switzerland and Stanford University. Ellen is an inventor on approximately 170 patents.
Jon Cassel, Ph.D, Senior Vice President, Operations
“Having spent most of my career prior to Genomic Health involved in the development and manufacturing of genomics and genetics technologies, it is profoundly gratifying to be now harnessing these to make such an important difference in the lives of so many cancer patients every day. The opportunity to translate great science and operational excellence so directly and immediately into improvements in clinical practice is a constant inspiration for all of us.”
With a passion for innovation in process development and operational excellence, Jon Cassel joined Genomic Health in 2007. Jon and his team bring extensive technical, operational, and clinical diagnostics experience to Genomic Health’s Clinical Laboratory, which delivers the results of our personalized genomic tests to physicians and their patients. In addition to the Clinical Laboratory, Jon leads a variety of other operational functions including Engineering, Manufacturing, Quality, Supply Chain, and Facilities. Prior to joining Genomic Health in 2007, Jon spent fifteen years at Applied Biosystems, a manufacturer of innovative integrated systems for nucleic acid and protein analysis, where he held leadership roles in manufacturing, process development, and product development. Jon contributed to the development, scale-up, and robust manufacturing of many of AB’s leading edge reagents for DNA sequencing, PCR, oligonucleotide synthesis, and related technologies as the genomic/genetic analysis field grew rapidly. Jon holds a Ph.D. in organic chemistry from the University of Wisconsin-Madison and a B.A. in chemistry from Albion College.